Reviewed by Michael Gill, B. Sc.
25 Als Clinical Trials Near Me
Top Hospitals for Als Clinical Trials
Image of Hospital for Special Surgery in New York.
Hospital for Special Surgery
New York
6Active Trials
17All Time Trials for Als
2012First Als Trial
Top Cities for Als Clinical Trials
Most Recent Als Clinical Trials
Top Treatments for Als Clinical Trials
Treatment Name
Active Als Clinical Trials
All Time Trials for Als
First Recorded Als Trial
Reldesemtiv
2
3
2017
AMX0035
2
5
2017
Pridopidine
2
2
2020
Mobile neural decoding platform (mobile iBCI)
1
1
2023
PTC857
1
1
2022
Recently Completed Studies with FDA Approved Treatments for Als
Treatment
Year
Sponsor
Theracurmin HP
2020
Richard Bedlack, M.D., Ph.D.

What Are ALS Trials?

ALS (Amyotrophic lateral sclerosis) is a nervous system disease that causes loss of muscle control. The progressive condition is often called Lou Gehrig disease, after the famous baseball player who was diagnosed with it. Stephen Hawking is another high-profile person who had the condition.

According to the Mayo Clinic, symptoms include:

  • Weakness in limbs
  • Muscle cramps and twitching
  • Difficulty swallowing
  • Slurred speech
  • Feeling clumsy or weak

ALS trials often focus on testing medications for the condition and their dosages and investigating potential new therapies. ALS trials also test technology to help those living with the condition communicate and live more independently.

For example, in 2002: BrainGate at Tufts University was in the pilot stage of trial testing BrainGate2 sensors in the motor-related cortex. Their goal is to identify ways to restore some functionality for people who have lost abilities such as speech.

Why Is ALS Being Studied Through Clinical Trials?

According to the CDC, around 31,000 people in the US live with ALS, with approximately 5,000 new cases each year. According to ALS Canada, there are 200,000 people worldwide that have ALS.

ALS’s rarity has meant a lack of patient/doctor options. According to the National Institute of Neurological Disorders and Strokes, the only FDA-approved drugs are Relyvrio, Riluzole, and Edaravone. Research is being done to help expand treatments and care provided to people with ALS.

What Are The Types Of Treatments Available For ALS?

According to the Mayo Clinic, treatments for ALS focus on trying to slow down the progression of the disease and help a person live as full a life as possible with the condition. However, there has yet to be a drug or therapy that can reverse the damage already caused by the disease.

Current FDA-approved drugs are:

  • Relyvrio
  • Riluzole (Rilutek)
  • Edaravone (Radicava)

Physical therapy assists patients in using their ever-changing bodies as best as possible. There are also breathing therapies, devices, and surgeries to help a person continue to breathe. ALS care teams also assist with nutrition plans, speech therapy, and occupational therapy.

Current trials are looking at new medications, dosages, therapies, and devices to help a person living with ALS.

What Are Some Recent Breakthrough Clinical Trials For ALS?

2000: Healey ALS Platform Trial – Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital, in partnership with Northeast ALS Consortium (NEALS), began enrolling participants for their “multicenter, double-blind, placebo-controlled, perpetual, adaptive platform trial.” They are looking at experimental treatments, including Zilucoplan, Verdiperstat, and CNM-Au8 nanocrystalline gold.

2000: CENTAUR Trial: Sean M. Healey & AMG Center for ALS concluded phase 3 of the trial of AMX035. Its success led to Amylyx receiving FDA approval for Relyvrio in 2022, which is two drugs: sodium phenylbutyrate and taurursodiol. The trial found that Relyvrio would slow the decline of a person with ALS and extend their life.

Who Are Some Of The Key Opinion Leaders / Researches In ALS Clinical Trial Research?

James Berry, MD, MPH, is the Director of the Massachusetts General Hospital Multidisciplinary ALS clinic, Director of the MGH Neurological Clinical Research Institute, and Chief of the Division of ALS and Motor Neuron Diseases. He focuses on ALS identification markers in the blood and spinal fluid.

P. Hande Ozdinler, Ph.D., leads the ALS research laboratory called The Ozdinler Lab. The lab focuses on motor neurons and the cellular and molecular mechanisms that can lead to their degeneration. Ozdinler is also an Associate Professor of Neurology at Northwestern University Feinberg School of Medicine. She was the senior author of the study that identified the first compound to repair degenerating upper motor neurons impacted by diseases such as ASL.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 25th, 2021

Last Reviewed: October 13th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Rosenbek JC, Robbins JA, Roecker EB, Coyle JL, Wood JL. A penetration-aspiration scale. Dysphagia. 1996 Spring;11(2):93-8. https://pubmed.ncbi.nlm.nih.gov/87210662 Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9. Review. https://pubmed.ncbi.nlm.nih.gov/114648473 Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999 Oct 31;169(1-2):13-21. https://pubmed.ncbi.nlm.nih.gov/105400024 Crary MA, Mann GD, Groher ME. Initial psychometric assessment of a functional oral intake scale for dysphagia in stroke patients. Arch Phys Med Rehabil. 2005 Aug;86(8):1516-20. https://pubmed.ncbi.nlm.nih.gov/160848015 Latham BD, Oskin DS, Crouch RD, Vergne MJ, Jackson KD. Cytochromes P450 2C8 and 3A Catalyze the Metabolic Activation of the Tyrosine Kinase Inhibitor Masitinib. Chem Res Toxicol. 2022 Sep 19;35(9):1467-1481. doi: 10.1021/acs.chemrestox.2c00057. Epub 2022 Sep 1. https://pubmed.ncbi.nlm.nih.gov/360488776 Glass JD, Boulis NM, Johe K, Rutkove SB, Federici T, Polak M, Kelly C, Feldman EL. Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells. 2012 Jun;30(6):1144-51. doi: 10.1002/stem.1079. https://pubmed.ncbi.nlm.nih.gov/224159427 Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, Hamada C, Kondo K, Yoneoka T, Akimoto M, Yoshino H; Edaravone ALS Study Group. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):610-7. doi: 10.3109/21678421.2014.959024. Epub 2014 Oct 6. https://pubmed.ncbi.nlm.nih.gov/252860158 Weiss JN, Levy S. Neurologic Stem Cell Treatment Study (NEST) using bone marrow derived stem cells for the treatment of neurological disorders and injuries: study protocol for a nonrandomized efficacy trial. Clin Trials Degener Dis. 2016 [cited 2019 Jun 18];1:176-80. 9 Boulis NM, Federici T, Glass JD, Lunn JS, Sakowski SA, Feldman EL. Translational stem cell therapy for amyotrophic lateral sclerosis. Nat Rev Neurol. 2011 Dec 13;8(3):172-6. doi: 10.1038/nrneurol.2011.191. Review. https://pubmed.ncbi.nlm.nih.gov/2215851810 Cella D, Nowinski C, Peterman A, Victorson D, Miller D, Lai JS, Moy C. The neurology quality-of-life measurement initiative. Arch Phys Med Rehabil. 2011 Oct;92(10 Suppl):S28-36. doi: 10.1016/j.apmr.2011.01.025. https://pubmed.ncbi.nlm.nih.gov/21958920